Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis

Digestive Diseases and Sciences

Volumn 44, Issue 10, 1999, Pages 2110-2118

  Kandil, Hossam M ^b   Argenzio, Robert A ^a   Sartor, R Balfour ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

Enterocolitis; Inflammation; Prostaglandin E2

Indexed keywords

INDOMETACIN; INTERLEUKIN 1ALPHA; MYELOPEROXIDASE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENTEROCOLITIS; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; RELAPSE; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENTEROCOLITIS; FEMALE; HUMANS; INDOMETHACIN; INTERLEUKIN-1; MISOPROSTOL; PEROXIDASE; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECURRENCE; SERUM ALBUMIN;

EID: 0032754893     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026694907238     Document Type: Article

References (63)

1. Nedwin GE, Svedersky LP, Bringman TS, Palladi MA,Goeddel DV: Effect of interleukin-2, interferon gamma andmitogen on the production of tumor necrosis factors-alpha andbeta. J Immunol 135:2492-2497, 1985
2. Dinarello C: Interleukin-1 and interleukin-1 antagonism.Blood 77:1627-1652, 1991
3. Movat HZ, Cybulsky MI, Colditz IG, Chan MK, Dinarello CA:Acute inflammation in gram-negative infection: Endotoxin,inlerleukin 1, tumor necrosis factor, and neutrophils. Fed Proc46:97-104, 1987
4. Movat HZ: Tumor necrosis factor and interleukin-1: Role inacute inflammation and microvascular injury. J Lab Clin Med157:413-420, 1987
5. Sartor RB: Current concepts of the etiology and pathogenesisof ulcerative colitis and Crohn's disease. Gastroenterol ClinNorth Am 24:475-507, 1995
6. Sartor RB: Cytokines in intestinal inflammation: Pathogenesisand clinical considerations. Gastroenterology 106:533-539,1994
7. Furie MB, McHugh DID: Migration of neutrophils acrossendothelial monolayers stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-α. J Immunol143:3309-3317, 1989
8. King JIW, Bersani L, Mantovani A: Tumor necrosis factor ischemotactic for monocytes and polymorphonuclear leukocytes.J Immunol 138:1469-1474, 1987
9. Walsh CJ, Leeper-Woodford SK, Carey PID, Cook IDJ, Bechard DE, Fowler AA, Sugerman HJ: CID 18 adhesion receptors, tumor necrosis factor, and neutropenia during septic lunginjury. J Surg Res 50:323-329, 1991
10. Le J, Vilcek J: Tumor necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab Invest56:234-238, 1987
11. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med320:365-376, 1989
12. Grisham MB, Granger DN: Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dig Sci 33:6S-15S, 1988
13. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, Sartor RB: Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant andsusceptible rats. Gastroenterology 106:960-972, 1994
14. 2 production is synergistically increased in cultured human glomerular mesangial cells by combinations of IL-1 and tumor necrosis factor-α. J Immunol 143:1989-1995, 1989
15. Cominelli F, Nast CC, Llerena R, Dinarello CA, Zipser RD:Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest 85:582-586,1990
16. Krzesicki RF, Hatfield CA, Bienkowski MJ, McGuire JC,Winterrowd GE, Chapman DL, Berger AE, McEwan RN,Carter DB, Chosay JG, Tracey DE, Chin JE: Regulation ofexpression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 150:4008-4018, 1993
17. Vane J: Towards a better aspirin. Nature 367:215-216, 1994
18. Jones DA, Carlton DP, Meintyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type 11 and demonstration of expression inresponse to cytokines. J Biol Chem 268:9049-9054, 1993
19. Dubois RN, Awad J, Morrow J, Roberts MJ, Bishop PR:Regulation of eicosanoid production and mitogenesis in ratintestinal epithelial cells by transforming growth factor-α andphorbol ester. J Clin Invest 93:493-498, 1994
20. Kargman S, Charleson S, Cartwrigh M, Frank J, Reindeau D,Mancini J, Evans J, O'Neil G: Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and humangastrointestinal tracts. Gastroenterology 111:448-454, 1996
21. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Balley D, Croxtall J, Willoughby DA: Inducible isoforms ofcyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91:2046-2050, 1994
22. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, HerschmanHR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3t3 cells, ecodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:1286-1272, 1991
23. Kandil H, Bersencider H, Argenzio RA: Tumor necrosis factor-α changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. Gut 35:934-940,1994
24. 2- Biochem Biophys Res Commun 137:404-410, 1986
25. Kunkel SL, Chensue SW, Phan SH: Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 136:186-192, 1986
26. Hogaboam CM, Bissonnette EY, Chin BC, Befus AD, WallaceJL: Prostaglandins inhibit inflammatory mediator release fromrat mast cells. Gastroenterology 104:122-129, 1993
27. Robert A: Cytoprotection by prostaglandins. Gastroenterology 77:761-767, 1979
28. Cohn SM, Schloemann S, Tessner T, Seiber K, Stenson WF:Crypt stem cell survival in mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-I. J Clin Invest 99:1367-1379, 1997
29. Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367, 1995
30. 4 synthesis. Gastroenterology 102:18-27, 1992
31. Whittle BJR: Temporal relationship between cyclooxygenaseinhibition, as measured by prostacyclin synthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94-98, 1981
32. 2. Gastroenterology 93:44-52, 1987
33. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL:Exacerbation of inflammation-associated colonic injury in ratsthrough inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085, 1996
34. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA,MacNaughton WK: Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Gastroenterology 115:101-109, 1998
35. Langenbach R, Morham SG, Tiano HF, Loftin CD, GhanayemBI, Chulada PC, Mahler JF, Lee CA, Goulding EH, KluckmanKD: Prostaglandin synthase 1 gene disruption in mice reducesarachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492, 1995
36. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O: Prostaglandin synthase 2 gene disruptioncauses severe renal pathology in the mouse. Cell 83:473-482,1995
37. Sartor RB, DelaCobna RA, Green KD, Standicki A, Davis SW, Schwab JH, Adam AA, Raymond P, Colman RW: Selectivekallikrein-kinin system activation in inbred rats differentiallysusceptible to granulomatous enterocolitis. Gastroenterology 110:1467-1481, 1996
38. Argenzio RA, Leece J, Powell DW: Prostaglandins inhibitintestinal NaCl absorption in experimental cryptosporidiosis. Gastroenterology 104:440-447, 1993
39. Cominelli F, Nast CC, Clark BD: Interleukin 1 (IL-1) geneexpression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86:972-980,1990
40. Krawisz JE, Sharon P, Stenson WF: Quantitative assay foracute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350, 1984
41. McCafferty DM, Mudgett JS, Swain MJ, Kubes P: Induciblenitric oxide synthase plays a critical role in resolving intestinalinflammation. Gastroenterology 112:1022-1027, 1997
42. Morris GP, Beck PL, Herridge MS, Depew WT, SzewezukMR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989
43. Yamada T, Marshall S, Specian RD, Grisham MB: A comparative analysis of two models-of-colitis in rats. Gastroenterology 102:1524-1534, 1992
44. Rampton DS, Hawkley CJ: Prostaglandins and ulcerative colitis. Gut 25:1399-1413, 1984
45. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada J:Participation of thromboxane and other eicosanoid synthesis inthe course of experimental inflammatory colitis. Gastroenterology 98:269-277, 1990
46. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB: Mechanism of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17:641-663, 1993
47. Wallace JL, Keenan CM, Granger DN: Gastric ulcerationinduced by nonsteroidal antiinflammatory drugs is a neutrophil-dependent process. Am J Physiol 259:G462-G467, 1990
48. Vallach DH, Holtmann H, Engelmann H, Nophar Y: Sensitization and desensitization to lethal effects of tumor necrosisfactor and IL-1. J Immunol 140:2994-2999, 1988
49. 49. Kaufmann HJ, Taubin HL: Nonsteroid anti-inflammatory drugs activate quiescent inflamatory bowel disease. Ann Intern Med 107:513-516, 1987
50. Higa A, McKnight GW, Wallace JL: Attenuation of epithelialinjury in acute experimental colitis by immunomodulators. EurJ Pharmacol 239:171-176, 1993
51. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F: Mucosal imbalance of IL-1 and IL-1 receptorantagonist in inflammatory bowel disease. A novel mechanismof chronic intestinal inflamation. J Immunol 154:2434-2440,1995
52. Isaacs KL, Sartor RB, Haskill S: Cytokine mRNA profile ininflammatory bowel disease mucosa detected by PCR amplification. Gastroenterology 103:1585-1595, 1992
53. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL: Inflammatory mediator-induced hypothalamic-pituitary-adrenal activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 86:2374-2378, 1989
54. Gupta RA, DuBois RN: Aspirin, NSAIDs, and colon cancerprevention: Mechanisms? Gastroenterology 114:1095-1100,1998
55. Giardiello FM, Hamilton SR, Crush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ:Treatment of colonic and rectal adenomas with sulindac infamilial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
56. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, BoriesC, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639, 1991
57. Nicholls RJ, Springall RG, Gallagher P: Regression of rectaladenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis. BMJ 296:1707-1708, 1988
58. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels inhuman colon cancer. J Lab Clin Med 122:518-523, 1993
59. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN: Up-regulation of cyclo-oxygenase-2 geneexpression in human colorectal adenomas and adenocarcino-mas. Gastroenterology 107:1183-1188, 1994
60. Tsujii M, Dubois RN: Alterations in cellular adhesion andapoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501, 1995
61. Jacoby RIF, Marshall DJ, Newton MA, Novakovic K, Cole CE,Lubet RA, Kelloff GJ, Verma A, Dove WF: Chemopreventionof spontaneous intestinal adenomas in the APC Min mousemodel by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710-714, 1996
62. Oshima M, Dinchuk JE, Kargman SIL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression ofintestinal polyposis in APC delta 716 Knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996
63. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T,Stenson W: Cyclooxygenase 2 is induced in colonic epithelialcells in inflammatory bowel disease. Gastroenterology 115:297-306, 1998